Drug Cos. Nervously Eye High Court In Landmark Case

Law360, New York (May 24, 2006, 12:00 AM EDT) -- One week after the Solicitor General recommended that the Supreme Court deny certiorari in the closely watched Schering-Plough case, the nation’s highest court is still contemplating whether to allow the case to go forward – but the stakes for generic companies, brand-name drug makers and consumers are only getting higher.

In an amicus curiae brief filed last week, the Solicitor General recognized the important issues concerning potential antitrust violations in patent settlements, but recommended against greenlighting the Schering-Plough case, saying it "does not present an appropriate...
To view the full article, register now.